PT2289540E - Alfa-1-antitripsina para usar no tratamento de síndrome de fadiga crónica - Google Patents
Alfa-1-antitripsina para usar no tratamento de síndrome de fadiga crónica Download PDFInfo
- Publication number
- PT2289540E PT2289540E PT103800710T PT10380071T PT2289540E PT 2289540 E PT2289540 E PT 2289540E PT 103800710 T PT103800710 T PT 103800710T PT 10380071 T PT10380071 T PT 10380071T PT 2289540 E PT2289540 E PT 2289540E
- Authority
- PT
- Portugal
- Prior art keywords
- quot
- aat
- alpha
- antitrypsin
- cfs
- Prior art date
Links
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title claims description 88
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title claims description 88
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title claims description 87
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 title claims description 76
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 title claims description 74
- 238000011282 treatment Methods 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000002753 trypsin inhibitor Substances 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 3
- 238000011269 treatment regimen Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 241000070928 Calligonum comosum Species 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 238000002406 microsurgery Methods 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 36
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 description 29
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 17
- 102000016387 Pancreatic elastase Human genes 0.000 description 16
- 108010067372 Pancreatic elastase Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 208000001640 Fibromyalgia Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000017854 proteolysis Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 206010014561 Emphysema Diseases 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000862 Ion Channels Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000008102 Ankyrins Human genes 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000009256 replacement therapy Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 3
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 3
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004647 pro-inflammatory pathway Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000005736 Nervous System Malformations Diseases 0.000 description 2
- 206010057244 Post viral fatigue syndrome Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000009461 neurocognitive dysfunction Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010005052 Bladder irritation Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030094 Odynophagia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 108010011767 m-calpain Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 229940075461 other therapeutic product in atc Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200930387A ES2332645B1 (es) | 2009-06-30 | 2009-06-30 | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2289540E true PT2289540E (pt) | 2012-12-04 |
Family
ID=41571181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT103800710T PT2289540E (pt) | 2009-06-30 | 2010-05-20 | Alfa-1-antitripsina para usar no tratamento de síndrome de fadiga crónica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205134B2 (https=) |
| EP (1) | EP2289540B1 (https=) |
| JP (1) | JP5231490B2 (https=) |
| CN (1) | CN101934071B (https=) |
| AR (1) | AR077123A1 (https=) |
| AU (1) | AU2010202203B2 (https=) |
| BR (1) | BRPI1002087B1 (https=) |
| CA (1) | CA2706212C (https=) |
| CL (1) | CL2010000575A1 (https=) |
| ES (2) | ES2332645B1 (https=) |
| MX (1) | MX2010006125A (https=) |
| NZ (1) | NZ585890A (https=) |
| PL (1) | PL2289540T3 (https=) |
| PT (1) | PT2289540E (https=) |
| RU (1) | RU2436590C1 (https=) |
| UY (1) | UY32670A (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2793936A4 (en) * | 2011-12-19 | 2015-05-27 | Lfb Usa Inc | RECOMBINANT HUMAN ALPHA-1-ANTITRYPINE FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US20220160847A1 (en) * | 2020-11-20 | 2022-05-26 | Mark Egly | Method of preventing and/or treating a plurality of diseases |
| WO2023184473A1 (zh) * | 2022-04-01 | 2023-10-05 | 首创生物技术有限公司 | 肽用于治疗神经退行性疾病或改善认知功能的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2281222A (en) * | 1941-09-27 | 1942-04-28 | American Bosch Corp | Speed regulator for internal combustion engines |
| US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| WO1992020327A1 (en) * | 1991-05-14 | 1992-11-26 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| AU3511500A (en) | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| CN1450898A (zh) * | 2000-04-21 | 2003-10-22 | 法玛西雅厄普约翰美国公司 | 用于治疗纤维肌痛和慢性疲劳综合症的化合物 |
| US20040043510A1 (en) * | 2000-07-14 | 2004-03-04 | Nobuyuki Shigetoh | Particle-labeled protein and immuno-chromatograph using the same |
| CA2506839A1 (en) | 2002-11-20 | 2004-06-03 | Prometic Biosciences, Inc. | Composition and method for treating inflammatory diseases using protease inhibitors |
| US7344882B2 (en) | 2003-05-12 | 2008-03-18 | Bristol-Myers Squibb Company | Polynucleotides encoding variants of the TRP channel family member, LTRPC3 |
| US7850970B2 (en) * | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| WO2006026837A1 (en) * | 2004-09-07 | 2006-03-16 | Patrick Englebienne | Diagnostic methods for measuring elastase activity levels |
| ES2281222B1 (es) * | 2004-09-24 | 2008-06-01 | Grifols, S.A. | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. |
| WO2008143633A2 (en) * | 2007-01-10 | 2008-11-27 | University Of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| WO2009042193A1 (en) * | 2007-09-25 | 2009-04-02 | Abbott Laboratories | Octahydropentalene compounds as chemokine receptor antagonists |
| PL2214699T3 (pl) | 2007-11-02 | 2017-05-31 | Grifols Therapeutics Inc. | Sposób, kompozycja i wyrób do dostarczania alfa1-antytrypsyny |
-
2009
- 2009-06-30 ES ES200930387A patent/ES2332645B1/es not_active Expired - Fee Related
-
2010
- 2010-05-20 PT PT103800710T patent/PT2289540E/pt unknown
- 2010-05-20 PL PL10380071T patent/PL2289540T3/pl unknown
- 2010-05-20 ES ES10380071T patent/ES2392691T3/es active Active
- 2010-05-20 EP EP10380071A patent/EP2289540B1/en active Active
- 2010-05-27 UY UY0001032670A patent/UY32670A/es not_active Application Discontinuation
- 2010-05-28 AU AU2010202203A patent/AU2010202203B2/en active Active
- 2010-06-02 NZ NZ585890A patent/NZ585890A/en not_active IP Right Cessation
- 2010-06-02 CL CL2010000575A patent/CL2010000575A1/es unknown
- 2010-06-03 MX MX2010006125A patent/MX2010006125A/es active IP Right Grant
- 2010-06-04 CA CA2706212A patent/CA2706212C/en active Active
- 2010-06-17 AR ARP100102142A patent/AR077123A1/es unknown
- 2010-06-24 US US12/822,764 patent/US9205134B2/en active Active
- 2010-06-24 BR BRPI1002087-0A patent/BRPI1002087B1/pt not_active IP Right Cessation
- 2010-06-29 JP JP2010147994A patent/JP5231490B2/ja active Active
- 2010-06-29 RU RU2010126653/15A patent/RU2436590C1/ru active
- 2010-06-30 CN CN2010102168418A patent/CN101934071B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2706212C (en) | 2014-02-04 |
| ES2332645B1 (es) | 2010-10-18 |
| ES2392691T3 (es) | 2012-12-12 |
| MX2010006125A (es) | 2011-01-05 |
| NZ585890A (en) | 2011-11-25 |
| EP2289540A1 (en) | 2011-03-02 |
| ES2332645A1 (es) | 2010-02-09 |
| HK1148198A1 (en) | 2011-09-02 |
| UY32670A (es) | 2011-01-31 |
| CL2010000575A1 (es) | 2011-10-28 |
| CA2706212A1 (en) | 2010-12-30 |
| BRPI1002087B1 (pt) | 2019-07-02 |
| RU2436590C1 (ru) | 2011-12-20 |
| AU2010202203B2 (en) | 2012-08-23 |
| EP2289540B1 (en) | 2012-08-22 |
| JP5231490B2 (ja) | 2013-07-10 |
| US9205134B2 (en) | 2015-12-08 |
| US20100331261A1 (en) | 2010-12-30 |
| AR077123A1 (es) | 2011-08-03 |
| JP2011012060A (ja) | 2011-01-20 |
| CN101934071B (zh) | 2012-11-28 |
| BRPI1002087A2 (pt) | 2012-03-13 |
| CN101934071A (zh) | 2011-01-05 |
| PL2289540T3 (pl) | 2013-03-29 |
| AU2010202203A1 (en) | 2011-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11400143B2 (en) | Compositions and methods for treatment of homocystinuria | |
| US20180153972A1 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency | |
| HK1250912A1 (en) | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency | |
| PT2289540E (pt) | Alfa-1-antitripsina para usar no tratamento de síndrome de fadiga crónica | |
| US20240279656A1 (en) | Engineered Guide RNAs and Polynucleotides | |
| WO2018183705A1 (en) | Oxidation-resistant aat gene therapy | |
| US20240091214A1 (en) | Lonafarnib for use in the treatment of viral infections | |
| Poppers | Anaesthetic implications of hereditary angioneurotic oedema | |
| KR20240021898A (ko) | 돌연변이된 아넥신 a5 폴리펩타이드 및 치료 목적을 위한 이의 용도 | |
| EP3813866B1 (en) | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure | |
| EP4203987A2 (en) | Compositions and methods for the treatment of ocular neuroinflammation | |
| EP4142775B1 (en) | Treatment and/or prevention of a disease or a syndrome related to a virus infection | |
| TWI800922B (zh) | 短胜肽、含有該短胜肽之水解物及其用於預防或/及治療神經損傷相關疾病之用途 | |
| HK1148198B (en) | Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome | |
| Bartsakoulia | Investigating the reversibility and tissue specificity of mitochondrial disorders | |
| EP1947115A2 (en) | Combination of glycoisoforms for the treatment or prevention of septicemia, transgenic cell line that produces erythropoietin glycoisoforms, pharmaceutical composition comprising said combination, method of obtaining the cell line, method of producing the combination of glycoisoforms and methods for the treatment and preven | |
| KR20210060574A (ko) | 응고 이상을 수반하는 패혈증의 치료 및/또는 개선을 위한 의약 | |
| UA137135U (uk) | Спосіб лікування хворих на хронічний панкреатит з метаболічним синдромом | |
| de BENTZMANN | 01 Virulence traits of P Aeruginosa are not static | |
| HK1220403B (en) | C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae). |